A prospective comparative study of intravesical chemotherapy versus immunotherapy in non-muscle invasive bladder cancer
DOI:
https://doi.org/10.18203/2349-2902.isj20252673Keywords:
Non-muscle invasive bladder cancer, BCG, Gemcitabine, Mitomycin C, Intravesical therapy, RecurrenceAbstract
Background: Non-muscle invasive bladder cancer (NMIBC) constitutes a significant proportion of urothelial malignancies. The optimal choice between intravesical chemotherapy and immunotherapy remains debatable, particularly regarding efficacy and recurrence rates. To prospectively compare the efficacy of intravesical chemotherapy and immunotherapy in NMIBC patients in terms of recurrence, progression, and therapy-related complications.
Methods: A randomized controlled trial was conducted on 56 NMIBC patients from March 2023 to March 2025 at GSVM Medical College, Kanpur. Patients were assigned to either intravesical chemotherapy (Arm A: Gemcitabine/Mitomycin C) or immunotherapy (Arm B: Bacillus Calmette-Guérin–BCG). They were followed for 9 months with regular cystoscopic evaluation. Clinical outcomes including recurrence and complications were analyzed.
Results: Recurrence was significantly lower in the immunotherapy group compared to chemotherapy (p<0.001). Histological subtype and tumor stage correlated with recurrence. Most recurrences occurred after 9 months. The immunotherapy group also showed a higher rate of bladder irritation and LUTS.
Conclusion: Intravesical BCG immunotherapy is superior in reducing recurrence compared to chemotherapy in NMIBC, although it is associated with increased local side effects. Larger, multicenter studies with extended follow-up are warranted.
Metrics
References
therapy for non-muscle invasive bladder cancer: A critical review. Curr Urol Rep. 2023;24(1):10-8.
Lammers RJ, Witjes WP, Janzing-Pastors MH. Intravesical gemcitabine versus mitomycin C in recurrent superficial bladder cancer: a randomized phase III study. Eur Urol. 2024;66(2):258-64.
Huncharek M, Muscat J, Kupelnick B. Intravesical chemotherapy for superficial transitional cell carcinoma of the bladder: A meta-analysis of randomized trials. J Clin Epidemiol. 2023;53(7):676-80. DOI: https://doi.org/10.1016/S0895-4356(99)00203-6
Lee HW, Seo GH, Ku JH. Clinical efficacy of neoadjuvant intravesical mitomycin-C therapy immediately before TURBT. Urology. 2020;136:121-7.
Shariat SF, Lotan Y, Karakiewicz PI. Outcomes of intravesical therapy for bladder cancer: Review of literature. Cancer. 2023;98(12):2560-71.
Kamat AM, Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. Urol Clin North Am. 2023;20(2):261-9.
Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6):2004-10. DOI: https://doi.org/10.1016/S0022-5347(06)00264-3
Ng K. The etiology of bladder cancer. Exon Publ. 2022;2:23-8. DOI: https://doi.org/10.36255/exon-publications-urologic-cancers-etiology-bladder-cancer